44:I[58016,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/050761d0d0bdc5d8.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/86498082dde169e6.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"ProcessEpisodeButton"] 46:I[185,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/050761d0d0bdc5d8.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/86498082dde169e6.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SendEmailButton"] 47:I[45269,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/050761d0d0bdc5d8.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/86498082dde169e6.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"SignupCTA"] 49:I[56939,["/_next/static/chunks/b5ea50e123aa84a6.js","/_next/static/chunks/050761d0d0bdc5d8.js","/_next/static/chunks/de880ec5a0241b38.js","/_next/static/chunks/48003610e91209eb.js","/_next/static/chunks/15a1b1fbd3cf7d4a.js","/_next/static/chunks/81ce7bf5f20dbd5a.js","/_next/static/chunks/86498082dde169e6.js","/_next/static/chunks/903c358828afe0bc.js","/_next/static/chunks/f63fb02bc4156bfb.js","/_next/static/chunks/88bed98e5cd5e639.js"],"EpisodeTranscript"] 3d:["$","svg",null,{"className":"w-4 h-4","fill":"none","stroke":"currentColor","viewBox":"0 0 24 24","children":["$","path",null,{"strokeLinecap":"round","strokeLinejoin":"round","strokeWidth":2,"d":"M8 7V3m8 4V3m-9 8h10M5 21h14a2 2 0 002-2V7a2 2 0 00-2-2H5a2 2 0 00-2 2v12a2 2 0 002 2z"}]}] 3e:["$","time",null,{"dateTime":"2026-03-05T04:00:00.000Z","children":"Thu Mar 05 2026"}] 45:T4e2,

touchPANEL DISCUSSION for touchONCOLOGY and touchRESPIRATORY

Listen to leading experts discuss the role of antibody–drug conjugates (ADCs) in NSCLC with brain metastases, including the latest clinical trial evidence, practical approaches to patient selection and treatment sequencing alongside local CNS therapies, and the evolving pipeline of investigational ADCs.

The expert(s)

Dr Lyudmila Bazhenova, Moore’s Cancer Center, San Diego, CA, USA
Dr Elvire Pons-Tostivint, Nantes Université, Centre Hospitalier Universitaire Nantes, France
Dr Julia Rotow, Dana-Farber Cancer Institute, Boston, MA, USA

This touchPODCAST is for HCPs only outside of the UK.

This activity is funded by an independent medical education grant fromAstraZeneca.

This activity is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.

For further information visit our websites:

Targeting brain metastases in advanced NSCLC: The emerging impact of ADCs